Transport
Mymichigan Medical Center Midland
Mymichigan Medical Center Midland was paid $50.05M by Medicaid between Jan 2018 and Dec 2024, across 460 billing codes. Its largest line is 99284, emergency room visit (serious) — 11% of everything it billed.
33Billing provider infoMYMICHIGAN MEDICAL CENTER MIDLAND
MIDLAND, MI 48670
MIDLAND, MI 48670
33aNPI1902841414assigned 06/18/2006
33bProvider typeLand Ambulance
28Total paid$50.05M
24GClaims1,681,104
24DCodes billed460
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Land Ambulance providers in Michigan
Rank by total paid#1 of 100
Median peer was paid$784K
This provider vs. median64×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JAMES, SARAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 187,528 | $4.56M | |
| 2019 | 205,226 | $5.03M | |
| 2020 | 199,822 | $5.02M | |
| 2021 | 242,826 | $6.80M | |
| 2022 | 282,713 | $9.10M | |
| 2023 | 304,354 | $10.21M | |
| 2024incomplete | 258,635 | $9.34M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 31,286 | 29,087 | $5.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 13,089 | 12,195 | $5.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 35,682 | 33,922 | $4.27M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.7% | 56,117 | 49,033 | $3.36M |
| A0425 | Ground mileage, per statute mile | 4.8% | 19,759 | 16,292 | $2.39M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 4.0% | 8,464 | 7,662 | $1.98M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 19,714 | 17,827 | $1.92M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 3.3% | 608 | 608 | $1.65M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 50,044 | 15,393 | $1.22M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 13,880 | 13,495 | $1.12M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 7,683 | 7,413 | $1.08M |
| 59025 | Fetal non-stress test | 1.9% | 10,242 | 4,785 | $947K |
448 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 29,212 | $762K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 9,351 | $751K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 1.4% | 3,203 | $715K |
| A0429 | Emergency ambulance ride, basic life support | 1.4% | 4,425 | $694K |
| G0379 | Direct admission of patient for hospital observation care | 1.3% | 1,102 | $650K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.3% | 18,306 | $628K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 20,322 | $616K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 19,473 | $593K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 6,290 | $571K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 3,262 | $563K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,812 | $474K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 3,542 | $459K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,441 | $443K |
| 80061 | Lipid panel | <1% | 17,034 | $442K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,899 | $413K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,062 | $401K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 22,437 | $321K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,596 | $306K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 7,067 | $299K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 623 | $298K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 11,825 | $246K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,955 | $231K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,535 | $225K |
| 76830 | Ultrasound, transvaginal | <1% | 3,589 | $212K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 9,945 | $211K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 612 | $210K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 17,495 | $201K |
| G0378 | Hospital observation service, per hour | <1% | 9,178 | $200K |
| 64493 | <1% | 289 | $193K | |
| 97162 | <1% | 3,559 | $187K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,677 | $186K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,760 | $184K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,838 | $182K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 24,582 | $169K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,052 | $165K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,133 | $161K |
| 20610 | <1% | 1,121 | $157K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,273 | $157K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,939 | $156K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,816 | $156K |
| 95912 | <1% | 522 | $151K | |
| 97161 | <1% | 2,759 | $139K | |
| 80053 | Comprehensive metabolic panel | <1% | 70,669 | $138K |
| 94060 | <1% | 977 | $133K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 170 | $128K |
| 86900 | <1% | 7,381 | $124K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 78,071 | $118K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 79,507 | $108K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 6,613 | $104K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,529 | $92K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,620 | $90K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,090 | $88K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,444 | $83K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 182 | $82K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 653 | $81K |
| 92526 | <1% | 1,668 | $76K | |
| 72141 | <1% | 517 | $75K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,371 | $67K |
| 93975 | <1% | 569 | $66K | |
| 62323 | <1% | 185 | $65K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,019 | $62K |
| 64635 | <1% | 57 | $61K | |
| 49083 | <1% | 159 | $61K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,294 | $58K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,011 | $58K |
| 76536 | <1% | 1,102 | $58K | |
| 93971 | <1% | 1,037 | $57K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,468 | $55K |
| 72100 | <1% | 1,599 | $52K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,376 | $52K |
| 97163 | <1% | 849 | $50K | |
| 76801 | <1% | 844 | $50K | |
| 97116 | <1% | 3,983 | $49K | |
| 72131 | <1% | 1,014 | $48K | |
| 76857 | <1% | 800 | $46K | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 3,725 | $46K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,173 | $45K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,727 | $45K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 352 | $43K |
| 93225 | <1% | 925 | $43K | |
| 93017 | <1% | 1,185 | $42K | |
| 96367 | <1% | 1,419 | $42K | |
| 76642 | <1% | 1,041 | $42K | |
| 82947 | <1% | 1,857 | $41K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,086 | $41K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,485 | $40K |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 1,976 | $39K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,051 | $37K |
| 76770 | <1% | 642 | $36K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,938 | $34K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,614 | $34K |
| 71271 | <1% | 573 | $34K | |
| 88342 | <1% | 1,385 | $34K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,773 | $34K |
| 93296 | <1% | 1,908 | $33K | |
| 87653 | <1% | 2,091 | $32K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,606 | $32K |
| 71250 | <1% | 561 | $31K | |
| 73564 | <1% | 1,966 | $31K | |
| 87808 | <1% | 4,693 | $30K | |
| 73030 | <1% | 2,242 | $30K | |
| 93351 | <1% | 140 | $29K | |
| 90474 | <1% | 4,229 | $29K | |
| 82607 | <1% | 4,105 | $28K | |
| 86803 | <1% | 4,325 | $27K | |
| 76775 | <1% | 726 | $27K | |
| 82728 | <1% | 4,018 | $27K | |
| 74018 | <1% | 1,450 | $26K | |
| 87070 | <1% | 6,907 | $26K | |
| 97166 | <1% | 486 | $25K | |
| 84439 | <1% | 6,093 | $25K | |
| 90670 | <1% | 3,306 | $24K | |
| 85027 | <1% | 11,058 | $22K | |
| 73630 | <1% | 2,572 | $22K | |
| 83970 | <1% | 1,118 | $21K | |
| 93970 | <1% | 208 | $21K | |
| 84702 | <1% | 4,419 | $21K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,771 | $20K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 24,030 | $19K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 69 | $19K |
| 70496 | <1% | 457 | $18K | |
| 73610 | <1% | 2,289 | $18K | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 283 | $17K |
| 73130 | <1% | 1,910 | $16K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,451 | $16K |
| 82746 | <1% | 2,243 | $16K | |
| 87186 | <1% | 5,518 | $16K | |
| 87081 | <1% | 9,794 | $15K | |
| 77065 | Tomosynthesis, mammo | <1% | 343 | $15K |
| 70491 | <1% | 142 | $15K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 7,255 | $15K |
| 81001 | <1% | 38,462 | $14K | |
| 70486 | <1% | 419 | $14K | |
| 87088 | <1% | 5,041 | $14K | |
| 83550 | <1% | 3,216 | $14K | |
| 81025 | <1% | 15,083 | $13K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 24 | $13K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 25 | $13K |
| 82043 | <1% | 3,900 | $12K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 632 | $12K |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 881 | $12K |
| 73110 | <1% | 1,443 | $12K | |
| 90480 | <1% | 276 | $12K | |
| 90686 | <1% | 4,277 | $12K | |
| 88307 | <1% | 1,241 | $12K | |
| 73502 | <1% | 876 | $11K | |
| 87077 | <1% | 4,274 | $11K | |
| 83880 | <1% | 3,748 | $11K | |
| 83540 | <1% | 3,526 | $11K | |
| 73221 | <1% | 93 | $11K | |
| 74019 | <1% | 633 | $11K | |
| 20611 | <1% | 86 | $11K | |
| 84481 | <1% | 1,176 | $10K | |
| 86038 | <1% | 1,754 | $10K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 499 | $10K |
| 86140 | <1% | 12,855 | $10K | |
| 86592 | <1% | 2,606 | $10K | |
| 77336 | <1% | 190 | $9K | |
| 84146 | <1% | 1,378 | $9K | |
| 83735 | <1% | 15,536 | $8K | |
| 80306 | <1% | 4,986 | $8K | |
| 73562 | <1% | 340 | $8K | |
| 80076 | <1% | 2,246 | $8K | |
| 87340 | <1% | 2,635 | $8K | |
| 84403 | <1% | 544 | $7K | |
| 97165 | <1% | 155 | $7K | |
| 88304 | <1% | 3,057 | $7K | |
| 77080 | <1% | 110 | $7K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 611 | $7K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 22 | $6K |
| 81002 | <1% | 2,819 | $6K | |
| 87075 | <1% | 2,391 | $6K | |
| 76870 | <1% | 273 | $6K | |
| 95811 | <1% | 14 | $6K | |
| 88112 | <1% | 309 | $5K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 25 | $5K |
| 85652 | <1% | 5,644 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,943 | $5K |
| 82570 | <1% | 2,385 | $5K | |
| 77334 | <1% | 20 | $5K | |
| 87276 | <1% | 13,225 | $5K | |
| 85610 | <1% | 12,128 | $5K | |
| 52000 | <1% | 24 | $4K | |
| 86481 | <1% | 89 | $4K | |
| 72040 | <1% | 186 | $4K | |
| 84153 | <1% | 432 | $4K | |
| 97035 | <1% | 772 | $4K | |
| 77300 | <1% | 44 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 53 | $4K |
| 84460 | <1% | 1,437 | $4K | |
| 86703 | <1% | 714 | $4K | |
| 87275 | <1% | 13,225 | $4K | |
| 84450 | <1% | 1,410 | $4K | |
| 83001 | <1% | 365 | $4K | |
| 93298 | <1% | 187 | $3K | |
| 73080 | <1% | 457 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 64 | $3K |
| 83690 | <1% | 13,607 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,526 | $3K |
| 95806 | <1% | 39 | $3K | |
| 80074 | <1% | 186 | $3K | |
| 87807 | <1% | 3,772 | $3K | |
| 92523 | <1% | 25 | $3K | |
| 86431 | <1% | 1,105 | $3K | |
| 82784 | <1% | 379 | $3K | |
| 84410 | <1% | 128 | $3K | |
| 90473 | <1% | 316 | $3K | |
| 86762 | <1% | 1,327 | $3K | |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 26 | $3K |
| 82950 | <1% | 928 | $3K | |
| 85730 | <1% | 4,552 | $2K | |
| 86706 | <1% | 496 | $2K | |
| 74183 | <1% | 12 | $2K | |
| 97014 | <1% | 312 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 191 | $2K |
| 82951 | <1% | 314 | $2K | |
| 82105 | <1% | 328 | $2K | |
| 82550 | <1% | 1,304 | $2K | |
| 29515 | <1% | 27 | $2K | |
| 84550 | <1% | 1,501 | $2K | |
| 93922 | <1% | 81 | $2K | |
| 73590 | <1% | 423 | $2K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 55 | $2K |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 43 | $2K |
| 58301 | <1% | 12 | $2K | |
| 77290 | <1% | 17 | $2K | |
| 83516 | <1% | 332 | $2K | |
| 81000 | <1% | 720 | $2K | |
| 90651 | <1% | 612 | $2K | |
| 72128 | <1% | 43 | $2K | |
| 73140 | <1% | 248 | $2K | |
| 80069 | <1% | 509 | $2K | |
| 93880 | <1% | 24 | $2K | |
| 87427 | <1% | 419 | $2K | |
| 84100 | <1% | 1,860 | $2K | |
| 95819 | <1% | 13 | $2K | |
| 85379 | <1% | 4,773 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,877 | $2K |
| 36591 | <1% | 90 | $2K | |
| 93226 | <1% | 1,033 | $2K | |
| 84703 | <1% | 4,902 | $2K | |
| 82565 | <1% | 686 | $1K | |
| 85018 | <1% | 1,785 | $1K | |
| 97167 | <1% | 36 | $1K | |
| 95816 | <1% | 12 | $1K | |
| 72110 | <1% | 63 | $1K | |
| 73523 | <1% | 26 | $1K | |
| 20605 | <1% | 13 | $1K | |
| 72050 | <1% | 28 | $1K | |
| 0001A | <1% | 34 | $1K | |
| 82248 | <1% | 544 | $1K | |
| 82670 | <1% | 83 | $1K | |
| 85014 | <1% | 1,493 | $1K | |
| 10060 | <1% | 12 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 104 | $1K |
| 90656 | <1% | 96 | $1K | |
| 75574 | <1% | 13 | $1K | |
| 72072 | <1% | 24 | $1K | |
| 51798 | <1% | 380 | $1K | |
| 71101 | <1% | 115 | $1K | |
| 83655 | <1% | 149 | $1K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 13 | $1K |
| 70498 | <1% | 451 | $971.00 | |
| 83615 | <1% | 830 | $967.17 | |
| 84156 | <1% | 1,128 | $941.76 | |
| 87046 | <1% | 314 | $922.94 | |
| 87045 | <1% | 313 | $919.95 | |
| 73090 | <1% | 425 | $918.64 | |
| 90734 | <1% | 717 | $901.95 | |
| 84402 | <1% | 69 | $866.73 | |
| 84484 | <1% | 12,585 | $827.88 | |
| 88173 | <1% | 49 | $767.47 | |
| 64494 | <1% | 257 | $745.43 | |
| 76641 | <1% | 12 | $733.58 | |
| 86704 | <1% | 152 | $732.93 | |
| 83002 | <1% | 78 | $725.34 | |
| 86200 | <1% | 129 | $718.12 | |
| 74022 | <1% | 389 | $647.98 | |
| 86308 | <1% | 784 | $618.33 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 51 | $613.80 |
| 0002A | <1% | 16 | $605.60 | |
| 76882 | <1% | 14 | $605.35 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 13 | $590.40 |
| 92611 | <1% | 14 | $583.84 | |
| 82962 | <1% | 20,752 | $583.31 | |
| 0071A | <1% | 19 | $581.40 | |
| 87040 | <1% | 3,259 | $549.77 | |
| 90716 | <1% | 611 | $519.78 | |
| 87522 | Neg quan hep c or qual rna | <1% | 27 | $517.68 |
| 88720 | <1% | 185 | $507.26 | |
| 97760 | <1% | 14 | $502.51 | |
| 94726 | <1% | 729 | $466.61 | |
| 0072A | <1% | 12 | $455.99 | |
| 93299 | <1% | 24 | $453.55 | |
| 96417 | <1% | 20 | $433.17 | |
| 86003 | <1% | 25 | $406.27 | |
| 87449 | <1% | 125 | $396.54 | |
| 72170 | <1% | 252 | $380.83 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 21 | $367.02 |
| 87220 | <1% | 822 | $348.04 | |
| 87324 | <1% | 97 | $327.59 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 305 | $318.40 |
| 84145 | <1% | 1,258 | $304.58 | |
| 86850 | <1% | 6,954 | $301.80 | |
| 93325 | <1% | 453 | $280.75 | |
| 87563 | <1% | 27 | $276.88 | |
| 87430 | <1% | 6,466 | $275.68 | |
| 83605 | <1% | 6,161 | $256.70 | |
| 86318 | <1% | 27 | $252.40 | |
| 83721 | <1% | 41 | $224.40 | |
| 84112 | <1% | 843 | $192.95 | |
| 87205 | <1% | 450 | $191.44 | |
| 86800 | <1% | 25 | $181.39 | |
| 86708 | <1% | 36 | $172.33 | |
| 82140 | <1% | 112 | $170.91 | |
| 86580 | <1% | 12 | $170.24 | |
| 73060 | <1% | 43 | $158.69 | |
| 80164 | <1% | 42 | $154.92 | |
| 83993 | <1% | 14 | $148.91 | |
| 88142 | <1% | 13 | $133.48 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 8,625 | $120.30 |
| G0008 | Administration of influenza virus vaccine | <1% | 28 | $112.00 |
| 82533 | <1% | 13 | $111.92 | |
| 82247 | <1% | 42 | $96.00 | |
| 82010 | <1% | 539 | $87.92 | |
| 84132 | <1% | 74 | $77.24 | |
| 83525 | <1% | 13 | $56.25 | |
| 84165 | <1% | 13 | $50.91 | |
| 88302 | <1% | 64 | $49.32 | |
| 87147 | <1% | 27 | $45.42 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 672 | $44.00 |
| 85046 | <1% | 13 | $40.59 | |
| 86225 | <1% | 12 | $39.50 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 21 | $39.15 |
| 85049 | <1% | 271 | $36.14 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,372 | $31.72 |
| 82310 | <1% | 12 | $31.55 | |
| 12001 | <1% | 528 | $27.68 | |
| 90672 | <1% | 268 | $26.88 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 12,393 | $15.10 |
| 82803 | <1% | 234 | $14.55 | |
| 82800 | <1% | 114 | $12.28 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 26,092 | $11.42 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,650 | $8.64 |
| 86901 | <1% | 7,378 | $8.31 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,203 | $4.20 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,638 | $3.33 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,081 | $3.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,022 | $3.00 |
| A9270 | Non-covered item or service | <1% | 3,772 | $1.22 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 2,575 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 11,948 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 128 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 5,210 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 291 | $0.00 |
| 96376 | 0% | 6,970 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 1,455 | $0.00 |
| 90647 | 0% | 3,381 | $0.00 | |
| 90680 | 0% | 3,117 | $0.00 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 67 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 704 | $0.00 |
| 90723 | 0% | 3,419 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 3,068 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 514 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 4,137 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 2,787 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 1,083 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 479 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 3,899 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,899 | $0.00 |
| 90696 | 0% | 826 | $0.00 | |
| C1769 | Guide wire | 0% | 2,181 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 766 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 2,367 | $0.00 |
| 95886 | 0% | 1,280 | $0.00 | |
| 96368 | 0% | 221 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 20 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 321 | $0.00 |
| 88341 | 0% | 263 | $0.00 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | 0% | 196 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 129 | $0.00 |
| J8501 | Aprepitant, oral, 5 mg | 0% | 562 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 211 | $0.00 |
| 74420 | 0% | 283 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 347 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 223 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 147 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 124 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 60 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 58 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 63 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 13 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 129 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 33 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 20 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 80 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 98 | $0.00 |
| 90620 | 0% | 26 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 58 | $0.00 |
| 12002 | 0% | 15 | $0.00 | |
| 80320 | 0% | 14 | $0.00 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 14 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 14 | $0.00 |
| A0888 | Noncovered ambulance mileage, per mile (e.g., for miles traveled beyond closest appropriate facility) | 0% | 12 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 891 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,996 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 2,077 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 3,624 | $0.00 |
| 93321 | 0% | 232 | $0.00 | |
| 90710 | 0% | 1,169 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 993 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 579 | $0.00 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 634 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 501 | $0.00 |
| 90707 | 0% | 666 | $0.00 | |
| 90633 | 0% | 2,209 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 7,298 | $0.00 |
| 94729 | 0% | 919 | $0.00 | |
| 90700 | 0% | 1,019 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 537 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 10,144 | $0.00 |
| 90715 | 0% | 2,574 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 1,600 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 1,257 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 4,910 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 504 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 643 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,518 | $0.00 |
| 29125 | 0% | 183 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 501 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 98 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 144 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 126 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 139 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 153 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 228 | $0.00 |
| 76942 | 0% | 15 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 58 | $0.00 |
| 12011 | 0% | 12 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 105 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 238 | $0.00 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | 0% | 110 | $0.00 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 40 | $0.00 |
| 91300 | 0% | 49 | $0.00 | |
| 64636 | 0% | 56 | $0.00 | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 15 | $0.00 |
| 76937 | 0% | 53 | $0.00 | |
| 64495 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJAMES, SARAH (MANAGER, PROVIDER ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.